<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38068427</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>23</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>28</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Effectiveness of Antiviral Therapy on Long COVID: A Systematic Review and Meta-Analysis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">7375</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm12237375</ELocationID><Abstract><AbstractText>Antiviral treatment reduces the severity and mortality of SARS-CoV-2 infection; however, its effectiveness against long COVID-19 is unclear. This study aimed to evaluate the effectiveness of antiviral drugs in preventing long COVID and related hospitalizations/deaths. Scientific and medical databases were searched from 1 January 2020 to 30 June 2023. We included observational cohort studies comparing individuals receiving early antiviral therapy for COVID-19 and those receiving supportive treatment. A fixed-effects model was used to merge the effects reported in two or more studies. The risk of post-acute sequelae of COVID-19 (PASC) was combined as an odds ratio (OR). Six studies were selected, including a total of 3,352,235 participants. The occurrence of PASC was 27.5% lower in patients who received antiviral drugs during the early stages of SARS-CoV-2 infection (OR = 0.725; 95% confidence interval [CI] = 0.409-0.747) than in the supportive treatment group. Moreover, the risk of PASC-associated hospitalization and mortality was 29.7% lower in patients receiving early antiviral therapy than in the supportive treatment group (OR = 0.721; 95% CI = 0.697-0.794). Early antiviral therapy was associated with a reduced risk of PASC and related hospitalization or death. Thus, early antiviral therapy is recommended for at-risk individuals.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Yu Jung</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul 02841, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vaccine Innovation Center-KU Medicine, Seoul 02841, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Yu Bin</ForeName><Initials>YB</Initials><AffiliationInfo><Affiliation>Division of Infectious Disease, Department of Internal Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul 07442, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Jun-Won</ForeName><Initials>JW</Initials><Identifier Source="ORCID">0000-0002-2806-1863</Identifier><AffiliationInfo><Affiliation>Departments of Internal Medicine, College of Medicine, Chosun University, Gwangju 61452, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jacob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Infectious Disease, Department of Internal Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul 07442, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nham</LastName><ForeName>Eliel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul 02841, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vaccine Innovation Center-KU Medicine, Seoul 02841, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seong</LastName><ForeName>Hye</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul 02841, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vaccine Innovation Center-KU Medicine, Seoul 02841, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Jin Gu</ForeName><Initials>JG</Initials><Identifier Source="ORCID">0000-0003-3283-1880</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul 02841, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vaccine Innovation Center-KU Medicine, Seoul 02841, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noh</LastName><ForeName>Ji Yun</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul 02841, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vaccine Innovation Center-KU Medicine, Seoul 02841, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheong</LastName><ForeName>Hee Jin</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul 02841, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vaccine Innovation Center-KU Medicine, Seoul 02841, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Woo Joo</ForeName><Initials>WJ</Initials><Identifier Source="ORCID">0000-0002-4546-3880</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul 02841, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Eun Jung</ForeName><Initials>EJ</Initials><Identifier Source="ORCID">0000-0003-2352-5267</Identifier><AffiliationInfo><Affiliation>Health, Welfare, Family and Gender Equality Team, National Assembly Research Service, Seoul 07233, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Joon Young</ForeName><Initials>JY</Initials><Identifier Source="ORCID">0000-0002-0148-7194</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul 02841, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vaccine Innovation Center-KU Medicine, Seoul 02841, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HD22C2045</GrantID><Agency>Korea Health Industry Development Institute</Agency><Country>Republic of Korea</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antiviral therapy</Keyword><Keyword MajorTopicYN="N">long COVID-19</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">post-acute sequelae</Keyword><Keyword MajorTopicYN="N">systemic review</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>9</Day><Hour>10</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>9</Day><Hour>10</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>9</Day><Hour>1</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38068427</ArticleId><ArticleId IdType="pmc">PMC10707593</ArticleId><ArticleId IdType="doi">10.3390/jcm12237375</ArticleId><ArticleId IdType="pii">jcm12237375</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization  . World Health Organization Coronavirus (COVID-19) Dashboard. World Health Organization; Geneva, Switzerland: 2022.  [(accessed on 26 July 2023)].  Available online:  https://covid19.who.int/</Citation></Reference><Reference><Citation>Han Q., Zheng B., Daines L., Sheikh A. Long-term sequelae of COVID-19: A systematic review and meta-analysis of one-year follow-up studies on post-COVID symptoms. Pathogens. 2022;11:269. doi: 10.3390/pathogens11020269.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens11020269</ArticleId><ArticleId IdType="pmc">PMC8875269</ArticleId><ArticleId IdType="pubmed">35215212</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M., Manoharan L., Elkheir N., Cheng V., Dagens A., Hastie C., O&#x2019;Hara M., Suett J., Dahmash D., Bugaeva P., et al. Characterising long COVID: A living systematic review. BMJ Glob. Health. 2021;6:e005427. doi: 10.1136/bmjgh-2021-005427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2021-005427</ArticleId><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman B., Cassar M.P., Tunnicliffe E.M., Filippini N., Griffanti L., Alfaro-Almagro F., Okell T., Sheerin F., Xie C., Mahmod M., et al. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. EClinicalmedicine. 2021;31:100683. doi: 10.1016/j.eclinm.2020.100683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100683</ArticleId><ArticleId IdType="pmc">PMC7808914</ArticleId><ArticleId IdType="pubmed">33490928</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H., Raza S., Nowell J., Young M., Edison P. Long covid-mechanisms, risk factors, and management. BMJ. 2021;374:n1648. doi: 10.1136/bmj.n1648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesan P. NICE guideline on long COVID. Lancet Respir. Med. 2021;9:129. doi: 10.1016/S2213-2600(21)00031-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00031-X</ArticleId><ArticleId IdType="pmc">PMC7832375</ArticleId><ArticleId IdType="pubmed">33453162</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler D.M. The costs of long COVID. JAMA Health Forum. 2022;3:e221809. doi: 10.1001/jamahealthforum.2022.1809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamahealthforum.2022.1809</ArticleId><ArticleId IdType="pubmed">36219031</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre C.H., Murray B., Varsavsky T., Graham M.S., Penfold R.S., Bowyer R.C., Pujol J.C., Klaser K., Antonelli M., Canas L.S., et al. Attributes and predictors of long COVID. Nat. Med. 2021;27:626&#x2013;631. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Chilunga F.P., Appelman B., van Vugt M., Kalverda K., Smeele P., van Es J., Wiersinga W.J., Rostila M., Prins M., Stronks K., et al. Differences in incidence, nature of symptoms, and duration of long COVID among hospitalised migrant and non-migrant patients in the Netherlands: A retrospective cohort study. Lancet Reg. Health Eur. 2023;29:100630. doi: 10.1016/j.lanepe.2023.100630.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2023.100630</ArticleId><ArticleId IdType="pmc">PMC10079482</ArticleId><ArticleId IdType="pubmed">37261215</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsampasian V., Elghazaly H., Chattopadhyay R., Debski M., Naing T.K.P., Garg P., Clark A., Ntatsaki E., Vassiliou V.S. Risk factors associated with post-COVID-19 condition: A systematic review and meta-analysis. JAMA Intern. Med. 2023;183:566&#x2013;580. doi: 10.1001/jamainternmed.2023.0750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.0750</ArticleId><ArticleId IdType="pmc">PMC10037203</ArticleId><ArticleId IdType="pubmed">36951832</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde M.W., Kim S.S., Lindsell C.J., Billig Rose E., Shapiro N.I., Files D.C., Gibbs K.W., Erickson H.L., Steingrub J.S., Smithline H.A., et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network&#x2014;United States, March&#x2013;June 2020. Morb. Mortal. Wkly. Rep. 2020;69:993&#x2013;998. doi: 10.15585/mmwr.mm6930e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6930e1</ArticleId><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitre T., Van Alstine R., Chick G., Leung G., Mikhail D., Cusano E., Khalid F., Zeraatkar D. Antiviral drug treatment for nonsevere COVID-19: A systematic review and network meta-analysis. CMAJ. 2022;194:E969&#x2013;E980. doi: 10.1503/cmaj.220471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.220471</ArticleId><ArticleId IdType="pmc">PMC9328465</ArticleId><ArticleId IdType="pubmed">35878897</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Long Hauler Advocacy Project &amp; Long Covid Community Responds to the Lack of Long Covid Awareness &amp; Education in President Biden&#x2019;s State of the Union.  [(accessed on 26 July 2023)].  Available online:  https://www.longhauler-advocacy.org/c-19lap-responds-to-sotu.</Citation></Reference><Reference><Citation>Hammond J., Leister-Tebbe H., Gardner A., Abreu P., Bao W., Wisemandle W., Baniecki M., Hendrick V.M., Damle B., Sim&#xf3;n-Campos A., et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N. Engl. J. Med. 2022;386:1397&#x2013;1408. doi: 10.1056/NEJMoa2118542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118542</ArticleId><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan Y., Puenpatom A., Johnson M.G., Zhang Y., Zhao Y., Surber J., Weinberg A., Brotons C., Kozlov R., Lopez R., et al. Impact of molnupiravir treatment on patient-reported coronavirus disease 2019 (COVID-19) symptoms in the Phase 3 MOVe-OUT trial: A randomized, placebo-controlled trial. Clin. Infect. Dis. 2023:ciad409. doi: 10.1093/cid/ciad409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad409</ArticleId><ArticleId IdType="pmc">PMC10686947</ArticleId><ArticleId IdType="pubmed">37466374</ArticleId></ArticleIdList></Reference><Reference><Citation>Cumpston M., Li T., Page M.J., Chandler J., Welch V.A., Higgins J.P., Thomas J. Updated guidance for trusted systematic reviews: A new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst. Rev. 2019;10:ED000142. doi: 10.1002/14651858.ED000142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.ED000142</ArticleId><ArticleId IdType="pmc">PMC10284251</ArticleId><ArticleId IdType="pubmed">31643080</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertuccio P., Degli Antoni M., Minisci D., Amadasi S., Castelli F., Odone A., Quiros-Roldan E. The impact of early therapies for COVID-19 on death, hospitalization and persisting symptoms: A retrospective study. Infection. 2023;51:1633&#x2013;1644. doi: 10.1007/s15010-023-02028-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-023-02028-5</ArticleId><ArticleId IdType="pmc">PMC10079146</ArticleId><ArticleId IdType="pubmed">37024626</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuang M.H., Wu J.Y., Liu T.H., Hsu W.H., Tsai Y.W., Huang P.Y., Lai C.C. Efficacy of nirmatrelvir and ritonavir for post-acute COVID-19 sequelae beyond 3 months of SARS-CoV-2 infection. J. Med. Virol. 2023;95:e28750. doi: 10.1002/jmv.28750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28750</ArticleId><ArticleId IdType="pubmed">37185834</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T.H., Wu J.Y., Huang P.Y., Tsai Y.W., Lai C.C. The effect of nirmatrelvir-ritonavir on the long-term risk of neuropsychiatric sequelae following COVID-19. J. Med. Virol. 2023;95:e28951. doi: 10.1002/jmv.28951.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28951</ArticleId><ArticleId IdType="pubmed">37436873</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Choi T., Al-Aly Z. Association of treatment with nirmatrelvir and the risk of post&#x2013;COVID-19 condition. JAMA Intern. Med. 2023;183:554&#x2013;564. doi: 10.1001/jamainternmed.2023.0743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.0743</ArticleId><ArticleId IdType="pmc">PMC10037200</ArticleId><ArticleId IdType="pubmed">36951829</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Choi T., Al-Aly Z. Molnupiravir and risk of post-acute sequelae of COVID-19: Cohort study. BMJ. 2023;381:e074572. doi: 10.1136/bmj-2022-074572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-074572</ArticleId><ArticleId IdType="pmc">PMC10126525</ArticleId><ArticleId IdType="pubmed">37161995</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirin A.A., Dimmock M.E., Jason L.A. Updated ME/CFS prevalence estimates reflecting post-COVID increases and associated economic costs and funding implications. Fatigue Biomed. Health Behav. 2022;10:83&#x2013;93. doi: 10.1080/21641846.2022.2062169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21641846.2022.2062169</ArticleId></ArticleIdList></Reference><Reference><Citation>Jason L.A., Mirin A.A. Updating the National Academy of Medicine ME/CFS prevalence and economic impact figures to account for population growth and inflation. Fatigue Biomed. Health Behav. 2021;9:9&#x2013;13. doi: 10.1080/21641846.2021.1878716.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21641846.2021.1878716</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirin A.A. A preliminary estimate of the economic impact of long COVID in the United States. Fatigue Biomed. Health Behav. 2022;10:190&#x2013;199. doi: 10.1080/21641846.2022.2124064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21641846.2022.2124064</ArticleId></ArticleIdList></Reference><Reference><Citation>Goggins S. Contesting public forgetting: Memory and policy learning in the era of COVID-19. Mem. Stud. 2023 doi: 10.1177/17506980231184563.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/17506980231184563</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W.J., Hui C.K.M., Hull J.H., Birring S.S., McGarvey L., Mazzone S.B., Chung K.F. Confronting COVID-19-associated cough and the post-COVID syndrome: Role of viral neurotropism, neuroinflammation, and neuroimmune responses. Lancet Respir. Med. 2021;9:533&#x2013;544. doi: 10.1016/S2213-2600(21)00125-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00125-9</ArticleId><ArticleId IdType="pmc">PMC8041436</ArticleId><ArticleId IdType="pubmed">33857435</ArticleId></ArticleIdList></Reference><Reference><Citation>Trypsteen W., Van Cleemput J., Snippenberg W.V., Gerlo S., Vandekerckhove L. LOn the whereabouts of SARS-CoV-2 in the human body: A systematic review. PLOS Pathog. 2020;16:e1009037. doi: 10.1371/journal.ppat.1009037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009037</ArticleId><ArticleId IdType="pmc">PMC7679000</ArticleId><ArticleId IdType="pubmed">33125439</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung C.C.L., Goh D., Lim X., Tien T.Z., Lim J.C.T., Lee J.N., Tan B., Tay Z.E.A., Wan W.Y., Chen E.X., et al. Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19. Gut. 2022;71:226&#x2013;229. doi: 10.1136/gutjnl-2021-324280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-324280</ArticleId><ArticleId IdType="pubmed">34083386</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., Kleine-Weber H., Schroeder S., Kr&#xfc;ger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A., et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271&#x2013;280.e8. doi: 10.1016/j.cell.2020.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki M., Saito J., Zhao H., Sakamoto A., Hirota K., Ma D. Inflammation triggered by SARS-CoV-2 and ACE2 augment drives multiple organ failure of severe COVID-19: Molecular mechanisms and implications. Inflammation. 2021;44:13&#x2013;34. doi: 10.1007/s10753-020-01337-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-020-01337-3</ArticleId><ArticleId IdType="pmc">PMC7541099</ArticleId><ArticleId IdType="pubmed">33029758</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabinger F., Stiller C., Schmitzov&#xe1; J., Dienemann C., Kokic G., Hillen H.S., H&#xf6;bartner C., Cramer P. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat. Struct. Mol. Biol. 2021;28:740&#x2013;746. doi: 10.1038/s41594-021-00651-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41594-021-00651-0</ArticleId><ArticleId IdType="pmc">PMC8437801</ArticleId><ArticleId IdType="pubmed">34381216</ArticleId></ArticleIdList></Reference><Reference><Citation>Kausar S., Said Khan F., Ishaq Mujeeb Ur Rehman M., Akram M., Riaz M., Rasool G., Hamid Khan A., Saleem I., Shamim S., Malik A. A review: Mechanism of action of antiviral drugs. Int. J. Immunopathol. Pharmacol. 2021;35:20587384211002621. doi: 10.1177/20587384211002621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20587384211002621</ArticleId><ArticleId IdType="pmc">PMC7975490</ArticleId><ArticleId IdType="pubmed">33726557</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou H., Tada T., Dcosta B.M., Landau N.R. Neutralization of SARS-CoV-2 omicron BA.2 by Therapeutic Monoclonal Antibodies. Biorxiv. 2022 doi: 10.1101/2022.02.15.480166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.02.15.480166</ArticleId><ArticleId IdType="pmc">PMC9228817</ArticleId><ArticleId IdType="pubmed">35746806</ArticleId></ArticleIdList></Reference><Reference><Citation>Cully M. A tale of two antiviral targets-and the COVID-19 drugs that bind them. Nat. Rev. Drug Discov. 2022;21:3&#x2013;5. doi: 10.1038/d41573-021-00202-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41573-021-00202-8</ArticleId><ArticleId IdType="pubmed">34857884</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahmah L., Abarikwu S.O., Arero A.G., Essouma M., Jibril A.T., Fal A., Flisiak R., Makuku R., Marquez L., Mohamed K., et al. Oral antiviral treatments for COVID-19: Opportunities and challenges. Pharmacol. Rep. 2022;74:1255&#x2013;1278. doi: 10.1007/s43440-022-00388-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43440-022-00388-7</ArticleId><ArticleId IdType="pmc">PMC9309032</ArticleId><ArticleId IdType="pubmed">35871712</ArticleId></ArticleIdList></Reference><Reference><Citation>Libster R., P&#xe9;rez Marc G., Wappner D., Coviello S., Bianchi A., Braem V., Esteban I., Caballero M.T., Wood C., Berrueta M., et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. N. Engl. J. Med. 2021;384:610&#x2013;618. doi: 10.1056/NEJMoa2033700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2033700</ArticleId><ArticleId IdType="pmc">PMC7793608</ArticleId><ArticleId IdType="pubmed">33406353</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb R.L., Vaca C.E., Paredes R., Mera J., Webb B.J., Perez G., Oguchi G., Ryan P., Nielsen B.U., Brown M., et al. Early remdesivir to prevent progression to severe COVID-19 in outpatients. N. Engl. J. Med. 2022;386:305&#x2013;315. doi: 10.1056/NEJMoa2116846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116846</ArticleId><ArticleId IdType="pmc">PMC8757570</ArticleId><ArticleId IdType="pubmed">34937145</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023;21:133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Glynne P., Tahmasebi N., Gant V., Gupta R. Long COVID following mild SARS-CoV-2 infection: Characteristic T cell alterations and response to antihistamines. J. Investig. Med. 2022;70:61&#x2013;67. doi: 10.1136/jim-2021-002051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jim-2021-002051</ArticleId><ArticleId IdType="pmc">PMC8494538</ArticleId><ArticleId IdType="pubmed">34611034</ArticleId></ArticleIdList></Reference><Reference><Citation>Nevalainen O.P.O., Horstia S., Laakkonen S., Rutanen J., Mustonen J.M.J., Kalliala I.E.J., Ansakorpi H., Kreivi H.R., Kuutti P., Paajanen J., et al. Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial. Nat. Commun. 2022;13:6152. doi: 10.1038/s41467-022-33825-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-33825-5</ArticleId><ArticleId IdType="pmc">PMC9579198</ArticleId><ArticleId IdType="pubmed">36257950</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>